沃森生物
(300142)
| 流通市值：197.61亿 | | | 总市值：203.12亿 |
| 流通股本：15.56亿 | | | 总股本：15.99亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,154,212,387 | 462,257,650.83 | 2,821,441,302.71 | 2,141,346,183.01 |
| 营业收入 | 1,154,212,387 | 462,257,650.83 | 2,821,441,302.71 | 2,141,346,183.01 |
| 二、营业总成本 | 975,738,044.24 | 426,650,521.54 | 2,531,774,103.41 | 1,756,031,473.68 |
| 营业成本 | 343,069,354.13 | 131,815,756.74 | 572,992,911.16 | 440,624,306.78 |
| 税金及附加 | 9,481,632.39 | 3,584,234.71 | 18,879,673.97 | 13,738,060.15 |
| 销售费用 | 376,601,671.18 | 164,337,868.79 | 978,830,738.2 | 680,700,809.17 |
| 管理费用 | 170,282,241.23 | 70,779,746.31 | 421,549,818.93 | 219,913,079.62 |
| 研发费用 | 120,802,796.56 | 66,903,745.93 | 596,544,738.98 | 431,105,368.12 |
| 财务费用 | -44,499,651.25 | -10,770,830.94 | -57,023,777.83 | -30,050,150.16 |
| 其中:利息费用 | -927,807.93 | 398,292.88 | 8,430,658.04 | 7,675,919.34 |
| 其中:利息收入 | 43,142,415.6 | 10,566,476.47 | 61,721,848.68 | 46,214,407.4 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 13,422,300 | 14,137,300 | -98,339,100 | -93,690,100 |
| 加:投资收益 | -486,057.34 | -136,299.58 | 5,025,931.85 | 4,896,943.05 |
| 资产处置收益 | 130,387.03 | 29,257.29 | -1,767,057.21 | -111,101.3 |
| 资产减值损失(新) | -131,388,229.06 | -52,046,616.43 | -174,204,510.83 | -98,210,651.5 |
| 信用减值损失(新) | -61,330,925.64 | -17,881,292.69 | 17,122,144.92 | 41,260,141.19 |
| 其他收益 | 15,106,458.84 | 6,714,452.6 | 59,169,449.96 | 46,623,025.57 |
| 四、营业利润 | 13,928,276.59 | -13,576,069.52 | 96,674,057.99 | 286,082,966.34 |
| 加:营业外收入 | 682,363.21 | 658,733.78 | 126,925,698.3 | 126,924,108.6 |
| 减:营业外支出 | 2,568,147.84 | 1,852,864.58 | 39,097,654.67 | 39,217,884.85 |
| 五、利润总额 | 12,042,491.96 | -14,770,200.32 | 184,502,101.62 | 373,789,190.09 |
| 减:所得税费用 | 19,136,733.95 | 4,912,458.72 | 10,104,226.38 | 23,148,305.19 |
| 六、净利润 | -7,094,241.99 | -19,682,659.04 | 174,397,875.24 | 350,640,884.9 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -7,094,241.99 | -19,682,659.04 | 174,397,875.24 | 350,640,884.9 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 43,160,638.4 | 2,646,248.58 | 142,160,410.01 | 256,358,619.72 |
| 少数股东损益 | -50,254,880.39 | -22,328,907.62 | 32,237,465.23 | 94,282,265.18 |
| 扣除非经常损益后的净利润 | 28,442,672.68 | -11,490,238.08 | 108,396,074.77 | 223,955,052.72 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.03 | 0 | 0.09 | 0.16 |
| (二)稀释每股收益 | 0.03 | 0 | 0.09 | 0.16 |
| 八、其他综合收益 | 39,950,000 | - | -45,900,000 | - |
| 归属于母公司股东的其他综合收益 | 39,950,000 | - | -45,900,000 | - |
| 九、综合收益总额 | 32,855,758.01 | -19,682,659.04 | 128,497,875.24 | 350,640,884.9 |
| 归属于母公司股东的综合收益总额 | 83,110,638.4 | 2,646,248.58 | 96,260,410.01 | 256,358,619.72 |
| 归属于少数股东的综合收益总额 | -50,254,880.39 | -22,328,907.62 | 32,237,465.23 | 94,282,265.18 |
| 公告日期 | 2025-08-26 | 2025-04-26 | 2025-04-12 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |